Search Result

Results for "

BRD4 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (25) Autophagy (3) Bcl-2 Family (1) c-Myc (4) Casein Kinase (1) Caspase (2) CDK (1) DNA-PK (1) DNA/RNA Synthesis (3) Epigenetic Reader Domain (164) ERK (2) HDAC (2) Histone Acetyltransferase (8) Histone Methyltransferase (1) HIV (3) JAK (1) Ligands for Target Protein for PROTAC (6) Molecular Glues (1) NAMPT (1) p38 MAPK (1) Parasite (1) PARP (3) PD-1/PD-L1 (1) PI3K (3) Polo-like Kinase (PLK) (4) PROTACs (10) SNIPERs (1) Src (1)
By Research Areas:	Cancer (150) Cardiovascular Disease (3) Infection (6) Inflammation/Immunology (28) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Androgen Receptor (1)

Apoptosis (25)

Autophagy (3)

Bcl-2 Family (1)

c-Myc (4)

Casein Kinase (1)

Caspase (2)

CDK (1)

DNA-PK (1)

DNA/RNA Synthesis (3)

Epigenetic Reader Domain (164)

ERK (2)

HDAC (2)

Histone Acetyltransferase (8)

Histone Methyltransferase (1)

HIV (3)

JAK (1)

Ligands for Target Protein for PROTAC (6)

Molecular Glues (1)

NAMPT (1)

p38 MAPK (1)

Parasite (1)

PARP (3)

PD-1/PD-L1 (1)

PI3K (3)

Polo-like Kinase (PLK) (4)

PROTACs (10)

SNIPERs (1)

Src (1)

By Research Areas:

Cancer (150)

Cardiovascular Disease (3)

Infection (6)

Inflammation/Immunology (28)

Metabolic Disease (1)

Neurological Disease (1)

172

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160499

BRD4 Inhibitor-30	Epigenetic Reader Domain	Cancer
BRD4 inhibitor-30 (Compound 1) is a *BRD4* inhibitor with a IC₅₀ value of 415 nM .

HY-146208

BRD4 Inhibitor-20	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC₅₀ values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer .

HY-143235

BRD4 Inhibitor-15	Epigenetic Reader Domain Apoptosis Bcl-2 Family Caspase c-Myc	Cancer
BRD4 Inhibitor-15 (compound 13) is a potent *BRD4* inhibitor, with an IC₅₀ of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research .

HY-155078

BRD4 Inhibitor-27	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-27 (compound 6) is a *BRD4* inhibitor with IC₅₀ of 9.6 and 11.3 μM for BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer .

HY-152209

BRD4 Inhibitor-26	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-26 is a bromodomain protein 4 (BRD4) inhibitor/nitric oxide-donator. BRD4 Inhibitor-26 inhibits BRD4 (BD1) and BRD4 (BD2) with IC₅₀ values of 0.82 μM and 1.94 μM, respectively. BRD4 Inhibitor-26 can be used for the research of ovarian cancer .

HY-160634

BRD4 Inhibitor-31	Epigenetic Reader Domain	Infection Inflammation/Immunology Cancer
BRD4 Inhibitor-31 (Example 136) is a *BRD4* inhibitor (K_is: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS .

HY-115926

BRD4 Inhibitor-16	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (BRD4). Overexpression of bromodomain 4 (BRD4) is closely correlated with a variety of human cancers by regulating the histone post-translational modifications. BRD4 Inhibitor-16 represents a useful tool for explorative studies of BRD4 inhibition, such as an improved understanding of BRD4 inhibitor release-related information .

HY-167871

BRD4 Inhibitor-36	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-36 (Compound 185) is a *BRD4* inhibitor. BRD4 Inhibitor-36 can be used for the research of cancer .

HY-146660

BRD4 Inhibitor-18	c-Myc Epigenetic Reader Domain Apoptosis	Cancer
BRD4 Inhibitor-18 is a highly potent *BRD4* inhibitor with an IC₅₀ value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level. BRD4 Inhibitor-18 has apoptosis-promoting and G0/G1 cycle-arresting activity .

HY-146739

BRD4 Inhibitor-19	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-19 is a BET* inhibitor* with an IC₅₀ of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research .

HY-147573

BRD4 Inhibitor-23	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-23 is a potent and orally active *BRD4* inhibitor with IC₅₀s of 6.21 nM and 1.44 nM for BRD4 BD-1 and BRD4 BD-2, respectively (WO2022033542A1; Example 1) .

HY-151972

BRD4 Inhibitor-25	Epigenetic Reader Domain	Cardiovascular Disease Inflammation/Immunology Cancer
BRD4 Inhibitor-25 is a *BRD4* inhibitor with IC₅₀s of 0.82 μM, 1.94 μM for BD1 and BD2 domains of BRD4. BRD4 Inhibitor-25 induces apoptotic and autophagy cell death in ovarian cancer cells. BRD4 Inhibitor-25 can be used in the research of cancers, cardiovascular, neuromuscular and inflammatory disorders.

HY-157460

BRD4 Inhibitor-29	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-29 (SQ-17) is a *BRD4* inhibitor, with an IC₅₀ of <100 nM. BRD4 Inhibitor-29 shows antiproliferative effect against prostate cancer cells .

HY-145909

BRD4 Inhibitor-17	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-17 (Compound 5i) is a potent inhibitor of *BRD4* with an IC₅₀ of 0.33 μM. BRD4 Inhibitor-17 plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. BRD4 Inhibitor-17 serves as potential antidotes for arsenicals .

HY-W192171

BRD4 Inhibitor-34	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-34 (Compound 12a) is a *BRD4* inhibitor with an IC₅₀ of 24 μM .

HY-132130

BRD4 Inhibitor-13	Epigenetic Reader Domain	Inflammation/Immunology Cancer
BRD4 Inhibitor-13 (Compound 2) is a *BRD4* ligand, and can be used for research of cancer, inflammation.

HY-132128

BRD4 Inhibitor-12	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-12 (Compound 9) is a *BRD4* ligand, and can be used for research of cancer, infammation .

HY-W806047

BRD4 Inhibitor-37	Others	Cancer
BRD4 Inhibitor-37 is a compound with anticancer activity that has inhibitory activity against BRD4. BRD4 Inhibitor-37 has an IC50 of approximately 0.05-0.1 μM in binding assays and shows a GI50 of 0.1-0.3 μM in cell-based assays. The effect of BRD4 Inhibitor-37 on c-Myc, a downstream protein of BRD4, has been validated, demonstrating its ability to intervene in this signaling pathway. BRD4 Inhibitor-37 exhibits selectivity among five different bromodomain proteins, enhancing its potential as a BET protein inhibitor .

HY-160636

BRD4 Inhibitor-32	Epigenetic Reader Domain	Others
BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

HY-160660

BRD4 Inhibitor-33	Epigenetic Reader Domain	Others
BRD4 Inhibitor-33 (example 13) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

HY-117491

BRD4 Inhibitor-10	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-10 is a potent *BRD4-BD1* inhibitor extracted from patent WO2015022332A1, Compound II-25, has an IC₅₀ of 8 nM .

HY-149519

BRD4 Inhibitor-28	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-28 (Compound 18) is an orally active *BRD4* Inhibitor. BRD4 Inhibitor-28 inhibits BRD40-BD1, BRD40-BD2 with IC₅₀s of 15, 55 nM. BRD4 Inhibitor-28 also inhibits BRD2-BD1, BRD3-BD1, BRDT-BD1 with IC₅₀s of 19, 25, 68 nM. BRD4 Inhibitor-28 has anti-melanoma activity .

HY-147202

BRD4 Inhibitor-24	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-24 (compound 3U) is a potent *BRD4* inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC₅₀ values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A) .

HY-160670

BRD4-IN-6	Epigenetic Reader Domain	Cancer
BRD4-IN-6 (compound 116) is a *BRD4* inhibitor (extracted from patent CN107721975A).

HY-160671

BRD4-IN-7	Epigenetic Reader Domain	Cancer
BRD4-IN-7 (compound 120) is a *BRD4* inhibitor(extracted from patent CN107721975A).

HY-117997

UMB-32	Epigenetic Reader Domain	Cancer
UMB-32, a potent, selective *BRD4* inhibitor, binds BRD4 with the K_d of 550 nM, and IC₅₀ of 637 nM. UMB-32 also shows potency against TAF1, a bromodomain-containing transcription factor .

HY-W265951

3-Methylcarbostyril	Epigenetic Reader Domain	Cancer
3-Methylcarbostyril (compound 5) is a BRD4 BD1 inhibitor with a pIC₅₀ of 4.4 .

HY-160672

BRD4-IN-8	Epigenetic Reader Domain	Cancer
BRD4-IN-8 (Example 13b) is a *BRD4* inhibitor .

HY-141843

BRD4-IN-2	Epigenetic Reader Domain	Inflammation/Immunology
BRD4-IN-2 is a bromodomain *BRD4* inhibitor with an IC₅₀ value of 9.9 nM.

HY-144338

PARP1/BRD4-IN-1	Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis	Cancer
PARP1/BRD4-IN-1 is a potent and high selective *PARP1/BRD4* inhibitor (IC₅₀s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .

HY-162892

BRD4-IN-9	Others	Cancer
BRD4-IN-9 is an orally active *BRD4* inhibitor with an IC₅₀ value of 9.4 nM. BRD4-IN-9 can suppress tumor growth in a mouse melanoma xenograft model .

HY-142674

BRD4-BD1/2-IN-1	Epigenetic Reader Domain	Cancer
BRD4-BD1/2-IN-1 is a potent *BRD4* inhibitor with IC₅₀s of <100 nM for BRD4 BD-1 and BRD4 BD-2, respectively (US20150148375A1, compound 5) .

HY-153751

BRD4-IN-4	Epigenetic Reader Domain	Cancer
BRD4-IN-4 (Compound 1) is a *BRD4* inhibitor (IC₅₀=6.83 μM). BRD4-IN-4 selectively inhibits MV4-11 cell line proliferation and arrests cell at G1 phase. BRD4-IN-4 can be used for research of MLL leukemia .

HY-104072

BRD4-IN-3	Epigenetic Reader Domain	Infection Inflammation/Immunology
BRD4-IN-3 (compound 141) is a potent *BRD4* inhibitor with an IC₅₀ of <0.5 µM. BRD4-IN-3 shows cytoxicity for MYC-Raji with an IC₅₀ value of >1 µM .

HY-142675

BRD4-BD1/2-IN-2	Epigenetic Reader Domain	Cancer
BRD4-BD1/2-IN-2 is a potent BRD4 BD2 inhibitor with IC₅₀s of <0.5 nM and <300 nM for BRD4 BD2 and BRD4 BD1, respectively (WO2021233371A1, compound 2) .

HY-163413

BRD4-BD1-IN-3	Epigenetic Reader Domain	Inflammation/Immunology
BRD4-BD1-IN-3 (Compound 4g) is a *BRD4-BD1* inhibitor. BRD4-BD1-IN-3 can be used for research of inflammatory disease .

HY-169170

PARP1/BRD4-IN-3	Apoptosis DNA/RNA Synthesis Epigenetic Reader Domain PARP	Cancer
PARP1/BRD4-IN-3 (compound HF4) is a potent *BRD4* and PARP1 inhibitor with IC₅₀ values of 1210, 2019 nM for BRD4, PARP1, respectively. PARP1/BRD4-IN-3 shows antiproliferative activities. PARP1/BRD4-IN-3 induces apoptosis and cell cycle arrest at G0/G1 phase. PARP1/BRD4-IN-3 causes DNA damage and reduces the protein expression of Rad51. PARP1/BRD4-IN-3 shows antitumor efficacy .

HY-161515

BRD4/NAMPT-IN-1	NAMPT Epigenetic Reader Domain	Cancer
BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and *BRD4* (IC₅₀=35 nM (NAMPT) and 58 nM (BRD4)). BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects .

HY-112149

ZL0420	Epigenetic Reader Domain	Inflammation/Immunology
ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC₅₀ values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

HY-160662

BRD4-IN-5	Epigenetic Reader Domain	Cancer
BRD4-IN-5 (example 51) is a *BRD4* inhibitor. The K_i values of the two BRD4 domains BDI_K57-E168 and BDII_E352-M457 are 9.7 nM and 16.1 nM, respectively. BRD4-IN-5 can be used in cancer research .

HY-142704

BRD4 D1-IN-1	Epigenetic Reader Domain	Cancer
BRD4 D1-IN-1 is a selective BRD4 D1 inhibitor (IC₅₀<0.092 µM). BRD4 D1-IN-1 has 18 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC .

HY-160558

PLK1/BRD4-IN-3	Epigenetic Reader Domain Polo-like Kinase (PLK)	Cancer
PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1). PLK1/BRD4-IN-3 inhibits BRD4-BD1, PLK1 and BRDT-BD1, with IC₅₀s of 0.059, 0.127 and 0.245 μM, respectively .

HY-111977

ZEN-3219	Epigenetic Reader Domain	Cancer
ZEN-3219 is a BET inhibitor with IC₅₀s of 0.48, 0.16 and 0.47 μM for *BRD4(BD1), BRD4(BD2)* and *BRD4(BD1BD2), respectively. ZEN-3219 can be used to form PROTACs to induce degradation of BRD4* .

HY-111979

ZEN-3411	Epigenetic Reader Domain	Cancer
ZEN-3411 is a BET inhibitor with IC₅₀s of 0.05, 0.05 and 0.06 μM for *BRD4(BD1), BRD4(BD2)* and *BRD4(BD1BD2), respectively. ZEN-3411 can be used to form PROTACs to induce degradation of BRD4* .

HY-143299

BRD4-BD1-IN-1	Epigenetic Reader Domain	Cancer
BRD4-BD1-IN-1 (Compound 9a) is a *BRD4-BD1* inhibitor with an IC₅₀ of 38.20 μM .

HY-142705

BRD4 D1-IN-2	Epigenetic Reader Domain	Cancer
BRD4 D1-IN-2 (compound 26) is a potent and selective BRD4 D1 inhibitor (IC₅₀<0.092 µM). BRD4 D1-IN-2 has 15 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC .

HY-111978

ZEN-3862	Epigenetic Reader Domain	Cancer
ZEN-3862 is a BET inhibitor with IC₅₀s of 0.16 and 0.13 μM for BRD4(BD1) and BRD4(BD2) , respectively. ZEN-3862 can be used to form PROTACs to induce degradation of BRD4 .

HY-150613

PARP1/BRD4-IN-2	Epigenetic Reader Domain PARP Apoptosis	Cancer
PARP1/BRD4-IN-2 is a potent and selective PARP1 and *BRD4* inhibitor with IC₅₀ values of 197 nM and 238 nM, respectively. PARP1/BRD4-IN-2 inhibits DNA damage repair, arrests G0/G1 transition and induces apoptosis. PARP1/BRD4-IN-2 has anti-tumor activity in MDA-MB-468 xenograft mouse model. PARP1/BRD4-IN-2 can be used for researching triple-negative breast cancer (TNBC) .

HY-143300

BRD4-BD1-IN-2	Epigenetic Reader Domain	Cardiovascular Disease Cancer
BRD4-BD1-IN-2 is a selective *BRD4-BD1* inhibitor, with an IC₅₀ of 2.51 µM (20-times greater than that of BD2). BRD4-BD1-IN-2 can be used in studies of cancer and cardiovascular diseases .

HY-103297

OXFBD02	Epigenetic Reader Domain	Cancer
OXF BD 02 is a selective inhibitor of *BRD4(1)* (the first bromodomain of BRD4) with IC₅₀ value of 382 nM .

Cat. No.	Product Name	Target	Research Area

HY-P10445

TAT-PiET	Epigenetic Reader Domain	Cancer
TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4 that disrupts the BRD4/JMJD6 interaction. BRD4/JMJD6 is a protein complex that is critical for oncogene expression and breast cancer, and TAT-PiET inhibits BRD4/JMJD6 target gene expression and breast cancer cell growth. TAT-PiET also resists endocrine resistance in ERα-positive breast cancer cells and is a potential inhibitor of breast cancer .

HY-P10446

TAT-PiET-PROTAC	Epigenetic Reader Domain	Cancer
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of *BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD4/JMJD6 and inhibit* the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: